Table 2.
Level of serum cytokines and chemokines (pg/mL) in MS patients at baseline and follow-up period.
| Cytokine | −2 weeks | 7 weeks | 10 weeks | 18 weeks | ||||
|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| TNF-α | 5.7 | 4.2–8.7 | 6.1 | 2.6–15.9 | 4.2 | 3.4–9.3 | 9.2 | 6.6–14.5 |
| IFN-γ | 155 | 107–226 | 155 | 58–332 | 100 | 33–203 | 171 | 91–360 |
| CCL4 | 337 | 311–378 | 293 | 208–429 | 337 | 229–441 | 278 | 216–394 |
| CCL2 | 97 | 78–123 | 90 | 57–142 | 82 | 49.3–111 | 86 | 64–98 |
| G-CSF | 9.5 | 5.7–23.2 | 10.2 | 7.2–14.6 | 9.0 | 5.6–18.6 | 12 | 8–32 |
| IL-1β | 2.5 | 2.4–4.0 | 3.6 | 2.9–6.4 | 2.9 | 2.3–3.2 | 3.2 | 3.1–3.7 |
| IL-2 | 1.4 | 0.4–22.4 | 0.4 | 0.4–1.6 | 0.7 | 0.4–10.7 | 0.5 | 0.4–10 |
| IL-4 | 1.6 | 1.2–3.7 | 1.5 | 1.3–2.8 | 1.6 | 1.0–2.2 | 1.6 | 1.3–2.6 |
| IL-5 | 5.6 | 3.6–7.8 | 4.7 | 3.2–9.3 | 4.9 | 3.0–7.2 | 6.4 | 3.4–9.2 |
| IL-6 | 8.6 | 5.6–14.3 | 9.6 | 3.4–14.8 | 8.7 | 5.1–16.6 | 8.5 | 5.7–13.3 |
| IL-7 | 15 | 12–23 | 12.1 | 5.8–17.2 | 12.5 | 9.4–13.6 | 11.5 | 9.2–13.6 |
| IL-8 | 25 | 16–39 | 23 | 17–146 | 19 | 16–35 | 20 | 16–30 |
| IL-10 | 14 | 7–25 | 12.4 | 6.3–15.2 | 9.5 | 6.3–16.8 | 12 | 7–19 |
| IL-12 | 23 | 17–67 | 18 | 13–28 | 17 | 11–60 | 32 | 16–57 |
| IL-13 | 4.4 | 2.7–6.8 | 3.2 | 2.7–7.0 | 3.7 | 2.9–4.8 | 4.9 | 3.6–6.0 |
| IL-17 | 9.3 | 4.6–19.7 | 10.4 | 3.6–18.8 | 11.3 | 4.6–17.1 | 11 | 3.9–14.1 |
| GM-CSF | Under detection limit | |||||||